Methods for shrinking pituitary tumors
Pituitary tumors may be reduced in size by administration of relacorilant. Pituitary tumors include, without limitation, non-secreting tumors, hormone-secreting tumors, adenomas, and carcinomas. Relacorilant administration may be effective to reduce hormone secretion from a hormone-secreting pituitary tumor, e.g., to reduce adrenocorticotrophic hormone (ACTH) secretion. A pituitary tumor may be imaged before and/or after relacorilant administration. Relacorilant may be administered independent of surgery, and before, during, or after surgery to treat a pituitary tumor. Relacorilant may aid or improve surgical outcomes, and may reduce the size or growth of pituitary tumor tissue before surgery, and any tumor tissue remaining following surgical treatment. Relacorilant may be orally administered for the treatment of pituitary tumors. Relacorilant may be orally administered to a fasted patient, or to a fed patient. Relacorilant may be administered in conjunction with other pituitary tumor targeting treatments, including surgical treatments, radiation treatments, chemotherapy for carcinomas, and other pharmaceutical treatments.
1. A method of reducing the size of a visible pituitary macroadenoma tumor in a patient suffering from said tumor, the tumor not having been treated with radiation, the method comprising imaging said visible pituitary macroadenoma tumor effective to determine a first size of said tumor, and then administering for three months to the patient daily oral doses of between about 100 milligrams (mg) and about 200 mg of relacorilant, where relacorilant is ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone), which has the following structure:
effective to reduce the size of the visible pituitary macroadenoma tumor from said first size of the visible pituitary macroadenoma tumor to a second size of the visible pituitary macroadenoma tumor, wherein said second size of the visible pituitary macroadenoma tumor is smaller than the first size of the visible pituitary macroadenoma tumor.
2. The method of claim 1 , further comprising determining that said patient suffers from a symptom of Cushing's syndrome.
3. The method of claim 1 , wherein said daily oral dose is selected from 100 mg, 150 mg, and 200 mg of relacorilant.
4. The method of claim 1 , further comprising measuring said visible pituitary macroadenoma tumor following relacorilant administration, wherein said measuring comprises a second imaging of the visible pituitary macroadenoma tumor.
5. The method of claim 4 , further comprising application of a further treatment directed to said visible pituitary macroadenoma tumor following said second imaging of the visible pituitary macroadenoma tumor.
6. The method of claim 5 , wherein said further treatment directed to said visible pituitary macroadenoma tumor comprises surgical treatment.
7. The method of claim 1 , wherein said visible pituitary macroadenoma tumor is a non-secreting pituitary tumor.
8. The method of claim 1 , wherein said visible pituitary macroadenoma tumor is a hormone-secreting tumor, wherein said hormone-secreting tumor secretes a first amount of hormone, and said treatment is effective to reduce the size of the visible pituitary macroadenoma tumor from said first size to said second size, and to reduce hormone secretion from said visible pituitary macroadenoma tumor from said first amount to a second amount of hormone secretion that is less than said first amount of hormone secretion.
9. The method of claim 1 , wherein said relacorilant administration comprises daily oral administration of relacorilant in one or more single unit dosage forms each containing an amount of relacorilant selected from 20 milligrams (mg), 50 mg, 100 mg, 150 mg, and 200 mg of relacorilant.
10. The method of claim 1 , wherein said administration of relacorilant comprises oral administration of relacorilant to a fasted patient.
11. The method of claim 10 , wherein said fasted patient is a patient who has not eaten a meal or otherwise ingested food for at least two hours prior to the administration of relacorilant.
12. The method of claim 1 , wherein said administration of relacorilant comprises oral administration of relacorilant to a fed patient.
13. The method of claim 12 , wherein said fed patient is a patient who has begun eating a meal about 30 minutes or less prior to the administration of relacorilant.
14. The method of claim 12 , wherein a fed patient is a patient who has begun eating a meal about one hour or less prior to the administration of relacorilant.
15. The method of claim 1 , wherein said administration of relacorilant comprises relacorilant administration prior to surgery for resection of the visible pituitary macroadenoma tumor.
16. The method of claim 1 , wherein said administration of relacorilant comprises relacorilant administration following surgery for resection of the visible pituitary macroadenoma tumor.
17. The method of claim 16 , wherein said relacorilant administration following surgery for resection of the visible pituitary macroadenoma tumor is effective to reduce the size of tumor tissue remaining in the patient following said surgical treatment from an unresected size to a smaller remaining size of tumor tissue, or to reduce the rate of growth of tumor tissue remaining in the patient following said surgical treatment from a first tumor growth rate to a second tumor growth rate smaller than said first tumor growth rate.
18. The method of claim 17 , further comprising administration of radiation treatment or cancer chemotherapy treatment, or both, to said patient receiving relacorilant administration following surgery for resection of the visible pituitary macroadenoma tumor.